Effect of Pembrolizumab (Keytruda®) on Biomarkers Related to Intratumoral Immunity, Proliferation and Apoptosis in Early ER/PR Negative Breast Cancer.
Not yet recruiting
Phase of Trial: Phase 0
Latest Information Update: 30 Oct 2017
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Breast cancer
- Focus Biomarker; Pharmacodynamics
- 24 Oct 2017 Planned initiation date changed from 1 Jul 2017 to 1 Nov 2017.
- 27 Jun 2017 New trial record